MedTrace Logo

The Potential Impact of Clindamycin on Neurosurgery Patients.

NCT06068673 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-01-19

No results posted yet for this study

Summary

A prospective, open-label, single center, controlled trial. 44 patients that underwent neurosurgery or presented meningitis signs, for whom Clindamycin add-on therapy to assess its effect on neurological complication in relation to Neuron-specific enolase (NSE) and Neurotensin biomarkers levels.

Conditions

  • Neurologic Complication
  • Neurosurgery

Interventions

DRUG

Clindamycin 600 mg

Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period.

DRUG

standard regimen

standard regimen

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass Prof. · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-12-01
Completion
2023-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068673 on ClinicalTrials.gov